Abstract
Cerebral venous thrombosis (CVT) is a potentially life-threatening condition requiring rapid diagnosis and urgent treatment. Heparin anticoagulation is the time-honoured treatment, and is advocated in all cases of CVT, irrespective of etiology or presence of haemorrhage. The supportive evidence is largely observational; data from randomized placebo-controlled trials shows a nonsignificant trend favouring heparin. Current practice is to begin heparin (unfractionated or low-molecular weight) immediately on confirmation of the diagnosis. Newer antithrombotic agents such as ximelagatran may offer advantages over heparin and need to be investigated in the treatment of CVT.
| Original language | English (UK) |
|---|---|
| Pages (from-to) | 541-543 |
| Number of pages | 3 |
| Journal | Journal of the Pakistan Medical Association |
| Volume | 56 |
| Issue number | 11 |
| Publication status | Published - Nov 2006 |